Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Financing › Details

Rinri Therapeutics–SEVERAL: investment, 202104 financing round £10m from existing investors + incl convertible loan from UK Future Fund

 

Period Period 2021-04-20
  Predecessor Rinri Therapeutics–SEVERAL: investment, 201905 seed financing round £1.4m co-led by BIVF + UCB Ventures
Organisations Money taker Rinri Therapeutics Ltd.
  Money source SEVERAL
Products Product stem cell therapy
  Product 2 venture capital
Person Person Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)
     

Rinri Therapeutics Ltd.. (4/20/21). "Press Release: Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss". Sheffield.

Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).

Rinri's underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hair cells in the cochlear and/or the auditory nerve. There are currently no pharmacological treatments available for SNHL despite the increasing number of patients that suffer from this condition globally.

Dr Simon Chandler, CEO of Rinri Therapeutics, commented: "We are very pleased to receive continuing support from existing investors alongside matched funding from the UK Future Fund. Our major investors share the vision we have for our technology to bring transformational changes to the lives of patients suffering from hearing loss, and the proceeds from this fund raising will allow us to advance our pioneering journey towards first in man clinical trials and to ultimately realise the potential of stem cell therapy to reverse sensorineural hearing loss."

Frank Kalkbrenner, Global Head of the Boehringer Ingelheim Venture Fund, added "We are delighted to continue our backing of Rinri and its pioneering approach to hearing loss, now with the added endorsement and support of the Future Fund. We believe Rinri's' technology is differentiated from other approaches to hearing loss restoration and has the potential to make a significant impact on treatment."

The UK Future Fund, launched in April 2020, issues convertible loans to private UK companies with good potential that typically rely on equity investment and are currently affected by COVID-19. The scheme is designed by UK government and delivered by the British Business Bank.


About Rinri Therapeutics

Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing. The company's pioneering technology seeks to reverse sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear. SNHL is estimated to affect 64 million patients in the US and 34 million in Europe. There are currently no pharmacological treatment options for SNHL patients.

Rinri, is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield. Rinri was founded in late-2018 and is headquartered in Sheffield, UK.


For more information, please visit: www.rinri-therapeutics.com

Contacts:

Rinri Therapeutics
Dr Simon Chandler, CEO
admin@rinri-therapeutics.com

Citigate Dewe Rogerson
Sylvie Berrebi, Frazer Hall
E: rinri@citigatedewerogerson.com
T: +44 (0)20 7638 9571

   
Record changed: 2021-04-28

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Rinri Therapeutics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top